Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants

被引:0
|
作者
Ehrenpreis, Eli D. [1 ]
Sifuentes, Humberto [1 ]
Ehrenpreis, Jamie E. [1 ]
Smith, Zachary L. [1 ]
Marshall, Mike L. [1 ]
机构
[1] NorthShore Univ Hlth Syst, Highland Pk Hosp, Ctr Study Complex Dis, Highland Pk, IL 60035 USA
关键词
adverse drug reactions; adverse events reporting system; FDA; nurse practitioners; pharmacology; pharmacovigilence; physician assistants; side effects; DRUG EVENTS; IMPACT;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: The Adverse Events Reporting System (AERS) of the FDA is used to identify toxicities of drugs that are on the market. Nurse practitioners (NP) and physician assistants (PA), having an increasing role in the delivery of medical care, are also needed to participate in post-marketing pharmacovigilance. This study was performed to assess awareness and use of the AERS in voluntary reporting of drug toxicities by NPs and PAs. Methods: A cluster sample survey was issued at the Principles of Gastroenterology for the Nurse Practitioner and Physician Assistant course in August 2010. The survey assessed familiarity with the AERS, the number of adverse events seen and the frequency of reports sent to the AERS. NP and PA responses were compared using the two-tailed Fisher's exact. Results: Of the 92 respondents, 67 (72%) were NPs and 24 (26%) PAs. Of the 50 (54%) respondents that reported being familiar with the AERS system, 20 (40%) incorrectly identified the methods to report using the AERS. Overall reporting of adverse events was low, particularly in respondents seeing 5-12 adverse events per year. Conclusion: The study suggests that improved education regarding the importance of using AERS for pharmacovigilance is suggested for NPs and PAs. Due to the small size of the study, these data should be viewed as preliminary, pending a larger confirmatory study.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 50 条
  • [41] Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system
    Liu, Ling
    Zhang, Chengyi
    Liu, Huihui
    Luo, Huan
    Cao, Rong
    Xiao, Mingxuan
    Zou, Pan
    Xie, Zhuzhu
    Gong, Hui
    Ma, Rui
    Yan, Miao
    Jiang, Zhichao
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (09) : 1199 - 1205
  • [42] PAIN AND ARTHRALGIA ADVERSE EVENTS ASSOCIATED WITH CRIZANLIZUMAB AND VOXELOTOR: DISPROPORTIONALITY ANALYSIS OF US FDA ADVERSE EVENTS REPORTING SYSTEM (FAERS)
    Ologunowa, A.
    Caffrey, A. R.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S208 - S208
  • [43] Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
    Pan, Xianglin
    Xiao, Xiangtian
    Ding, Yiling
    Shu, Yamin
    Zhang, Wenting
    Huang, Liu
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [44] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System DatabaseA Disproportionality Analysis
    Behrooz K. Shamloo
    Pankdeep Chhabra
    Andrew N. Freedman
    Arnold Potosky
    Jennifer Malin
    Sheila Weiss Smith
    [J]. Drug Safety, 2012, 35 : 507 - 518
  • [45] Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
    Shu, Yamin
    Chen, Jing
    Ding, Yiling
    Zhang, Qilin
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    [J]. HELIYON, 2024, 10 (14)
  • [47] Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
    Shu, Yamin
    He, Xucheng
    Wu, Pan
    Liu, Yanxin
    Ding, Yufeng
    Zhang, Qilin
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [48] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis
    Shamloo, Behrooz K.
    Chhabra, Pankdeep
    Freedman, Andrew N.
    Potosky, Arnold
    Malin, Jennifer
    Smith, Sheila Weiss
    [J]. DRUG SAFETY, 2012, 35 (06) : 507 - 518
  • [49] Cardiovascular adverse events associated with parp inhibitors: A disproportionality analysis of FDA adverse event reporting system
    Viswam, Subeesh Kulangara
    Kheterpal, Aarushi
    Dhas, Ashwin
    Zeba, Zeba
    Shettigar, Amrutha
    Lukose, Lipin
    Kaur, Gursimran
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 452 - 452
  • [50] Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database
    Roberto, Giuseppe
    Piccinni, Carlo
    D'Alessandro, Roberto
    Poluzzi, Elisabetta
    [J]. CEPHALALGIA, 2014, 34 (01) : 5 - 13